Compass Therapeutics Inc. (CMPX) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Compass Therapeutics Inc. (NASDAQ: CMPX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $0.76 (-0.54% 1D, market cap $136.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CMPX ranks #381 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CMPX carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -34.6%. By comparison, CHRS (Coherus Oncology Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $138.8M) and MOLN (Molecular Partners AG) posts a D grade (50/100 RQD, P/E N/A, ROIC —, cap $132.4M). Among the 5-stock peer group, CMPX leads on earnings multiple (N/A) while CMPX leads on capital efficiency (-34.6% ROIC).
Per CMPX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001738021), Compass Therapeutics Inc. generated $0 in revenue, -$66.5M in net income, and -$49.2M in free cash flow against $219.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While CMPX currently carries a cautious 46/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.46) and Max Pain ($0.80) forces dealer call-delta covering toward $7.22.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Compass Therapeutics Inc. (CMPX) slipped -0.54% to $0.76, trading at 2% of its 52-week range ($0.73 – $6.88). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
As published in the Journal of Clinical Oncology (JCO) and presented at ESMO, COMPANION-002 met its primary endpoint of ORR and key secondary endpoint of PFS, with a 56% reduction in the risk of disease progression or de
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CMPX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CMPX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Compass Therapeutics Inc. (CMPX) ranks #381 by composite RQD confidence (46/100, grade D) and #620 by equity capitalization ($136.2M). Within this direct 5-issuer industry benchmark cohort, CMPX leads on earnings valuation at N/A trailing P/E, while CMPX leads on capital efficiency and profitability with -34.6% ROIC and — gross margin. CRDL currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with CMPX at 46/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CMPX
ACTIVE
Compass Therapeutics Inc. | D | 46/100 | — | — | -34.6% | -0.54% | $136.2M | Benchmark Subject |
| CHRS Coherus Oncology Inc. | D- | 36/100 | — | — | -35.0% | -22.55% | $138.8M | /chrs-vs-cmpx → |
| MOLN Molecular Partners AG | D | 50/100 | — | — | — | -4.88% | $132.4M | /moln-vs-cmpx → |
| CRDL Cardiol Therapeutics Inc. (Class A) | D+ | 52/100 | — | — | — | 0.00% | $141.2M | /crdl-vs-cmpx → |
| HUMA Humacyte Inc. | E | 31/100 | — | -30.0% | -35.0% | -0.06% | $130.5M | /huma-vs-cmpx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Compass Therapeutics Inc. (CMPX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$66.5M, operating cash flow of -$49.1M, and free cash flow of -$49.2M (-9.5% YoY). On the balance sheet, CMPX closed FY2025 with $219.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$66.5M | -$49.1M | -$49.2M | $219.6M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$49.4M | -$44.9M | -$44.9M | $140.4M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$42.5M | -$40.6M | -$40.6M | — | — |
As of 2026-11-02, Compass Therapeutics Inc. (NASDAQ: CMPX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $0.76 (-0.54% 1D, market cap $136.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CMPX ranks #381 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CMPX carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -34.6%. By comparison, CHRS (Coherus Oncology Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $138.8M) and MOLN (Molecular Partners AG) posts a D grade (50/100 RQD, P/E N/A, ROIC —, cap $132.4M). Among the 5-stock peer group, CMPX leads on earnings multiple (N/A) while CMPX leads on capital efficiency (-34.6% ROIC).
Per CMPX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001738021), Compass Therapeutics Inc. generated $0 in revenue, -$66.5M in net income, and -$49.2M in free cash flow against $219.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
CMPX last traded at $0.76 (-0.54% on volume of 2,025,426 shares), positioning the stock -47.95% below its 50-day simple moving average ($1.46) and -76.18% below its 200-day simple moving average ($3.19). Across its 52-week range of $0.73 to $6.88, CMPX sits at the 0.5% percentile with a 14-day RSI of 27.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.86).
Why CMPX Stock slipped -0.54% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).